AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?

Content Provider	Europe PMC
Author	Oo, Wai M. Giri, Pradeep de Souza, Aaron
Copyright Year	2021
Abstract	The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8447540&blobtype=pdf
ISSN	01655728
Journal	Journal of Neuroimmunology [J Neuroimmunol]
Volume Number	360
DOI	10.1016/j.jneuroim.2021.577719
PubMed Central reference number	PMC8447540
PubMed reference number	34560365
e-ISSN	18728421
Language	English
Publisher	Published by Elsevier B.V.
Publisher Date	2021-09-17
Access Restriction	Open
Rights License	Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Crown Copyright © 2021 Published by Elsevier B.V. All rights reserved.
Subject Keyword	Guillain-Barre syndrome Inflammatory demyelinating polyneuropathy COVID-19 AstraZeneca vaccine COVID-19 vaccine Chronic inflammatory demyelinating polyneuropathy (CIDP) GBS, Guillain- Barré Syndrome CIDP, Chronic inflammatory demyelinating polyneuropathy IDP, Inflammatory demyelinating polyneuropathy CSF, Cerebrospinal Fluid IVIG, Intravenous immune globulin ICU, Intensive care unit AZ, AstraZeneca Vaccine/ ChAdOx1 nCoV-19 vaccine SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 ACE2 receptor, Angiotensin-converting enzyme 2 receptor NCV, nerve conduction velocity
Content Type	Text
Resource Type	Article
Subject	Neurology Immunology and Allergy Neurology (clinical) Immunology